ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Refractory Cancer · Recurrent Cancer · Solid Tumor, Adult · Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford Cancer Institute, Stanford, California, United States
Contact: Study coordinator (Allison Warner, MD) · allison.betof@stanford.edu
University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States
Contact: Study coordinator (Sapna Patel, MD) · 720-848-0000
University of Miami Hospital and Clinics, Miami, Florida, United States
Study coordinator · CRSCutaneous@miami.edu · 305-243-2647
University of Chicago Medical Center, Chicago, Illinois, United States
Contact: Study coordinator (Katherine Kurnit, MD)
Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Study coordinator (Oldadapo O. Yeku, MD. PhD) · 617-643-6158
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Alexander Shoushtari, MD) · shoushta@mskcc.org · 646-888-4161
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus, Ohio, United States
Contact: Study coordinator (Casey Cosgrove, MD) · Casey.Cosgrove@osumc.edu
University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Janos Tanyi, MD, PhD) · Janos.Tanyi@pennmedicine.upenn.edu
Thomas Jefferson University, Honickman Center, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Rino Seedor, MD) · Rino.Seedor@jefferson.edu · 215-847-7409
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Anthony Olszanski, MD, RPh) · Anthony.Olszanski@fccc.edu
Contact: Principal Investigator (Anthony Olszanski, MD)
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Diwakar Davar, M.D.) · davard@upmc.edu · 412-623-7368
Contact: Principal Investigator (Jason Luke, M.D.)
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Dejka M Araujo, M.D.) · daraujo@mdanderson.org · 713-792-3626
Contact: Principal Investigator (Dejka M Araujo, M.D.)
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Contact: Study coordinator (Sylvia Lee, MD) · leesm@uw.edu
Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Baden-Wurttemberg, Germany
Klinikum rechts der Isar der Technischen Universität München, Munich, Bavaria, Germany
Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
Universitätsklinikum Bonn - Medizinische Klinik III, Bonn, North Rhine-Westphalia, Germany
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Rhineland-Palatinate, Germany
Universitätsklinikum C.-G.-Carus Dresden, Dresden, Saxony, Germany
Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie, Berlin, Germany
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Study leads

Cedrik Britten, M.D.
Study Director
Immatics US, Inc.

View source on ClinicalTrials.gov Contact study team (email)